1. Home
  2. BEAM vs AGM Comparison

BEAM vs AGM Comparison

Compare BEAM & AGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • AGM
  • Stock Information
  • Founded
  • BEAM 2017
  • AGM 1987
  • Country
  • BEAM United States
  • AGM United States
  • Employees
  • BEAM N/A
  • AGM N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • AGM Finance Companies
  • Sector
  • BEAM Health Care
  • AGM Finance
  • Exchange
  • BEAM Nasdaq
  • AGM Nasdaq
  • Market Cap
  • BEAM 1.6B
  • AGM 2.1B
  • IPO Year
  • BEAM 2020
  • AGM N/A
  • Fundamental
  • Price
  • BEAM $20.01
  • AGM $201.02
  • Analyst Decision
  • BEAM Strong Buy
  • AGM Hold
  • Analyst Count
  • BEAM 11
  • AGM 1
  • Target Price
  • BEAM $48.90
  • AGM $215.00
  • AVG Volume (30 Days)
  • BEAM 2.0M
  • AGM 201.5K
  • Earning Date
  • BEAM 08-05-2025
  • AGM 08-04-2025
  • Dividend Yield
  • BEAM N/A
  • AGM 2.98%
  • EPS Growth
  • BEAM N/A
  • AGM N/A
  • EPS
  • BEAM N/A
  • AGM 16.17
  • Revenue
  • BEAM $63,578,000.00
  • AGM $357,515,000.00
  • Revenue This Year
  • BEAM N/A
  • AGM $9.70
  • Revenue Next Year
  • BEAM $8.82
  • AGM $8.26
  • P/E Ratio
  • BEAM N/A
  • AGM $12.43
  • Revenue Growth
  • BEAM N/A
  • AGM N/A
  • 52 Week Low
  • BEAM $13.53
  • AGM $159.64
  • 52 Week High
  • BEAM $35.25
  • AGM $217.60
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 68.31
  • AGM 63.29
  • Support Level
  • BEAM $16.59
  • AGM $192.83
  • Resistance Level
  • BEAM $17.38
  • AGM $199.75
  • Average True Range (ATR)
  • BEAM 1.10
  • AGM 4.27
  • MACD
  • BEAM 0.35
  • AGM 0.74
  • Stochastic Oscillator
  • BEAM 89.70
  • AGM 93.68

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About AGM Federal Agricultural Mortgage Corporation

Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.

Share on Social Networks: